tetano
Editor, Senior Moderator
Value Health
. 2022 Feb 20;S1098-3015(22)00044-4.
doi: 10.1016/j.jval.2021.12.015. Online ahead of print.
A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales
Rachid Rafia[SUP] 1 [/SUP], Marrissa Martyn-St James[SUP] 1 [/SUP], Sue Harnan[SUP] 1 [/SUP], Andrew Metry[SUP] 2 [/SUP], Jean Hamilton[SUP] 1 [/SUP], Allan Wailoo[SUP] 1 [/SUP]
Affiliations
Abstract
Objectives: COVID-19 is associated with significant morbidity and mortality. This study aims to synthesize evidence to assess the cost-effectiveness of remdesivir (RDV) for the treatment of hospitalized patients with COVID-19 in England and Wales.
Methods: A probabilistic cost-effectiveness analysis was conducted informed by 2 large trials and uses a partitioned survival approach to assess short- and long-term clinical consequences and costs associated with COVID-19 in a hypothetical cohort of hospitalized patients requiring supplemental oxygen at the start of treatment. Given that it is uncertain whether RDV reduces death, 2 analyses are presented, assuming RDV either reduces death or does not. Published sources were used for long-term clinical, quality of life, and cost parameters.
Results: Under the assumption that RDV reduces death, the incremental cost-effectiveness ratio for RDV is estimated at £11 881 per quality-adjusted life-year gained compared with standard of care (SoC) (probabilistic incremental cost-effectiveness ratio £12 400). The probability for RDV to be cost-effective is 74% at a willingness-to-pay threshold of £20 000 per quality-adjusted life-year gained. RDV was no longer cost-effective when the hazard ratio for overall survival compared with SoC was >0·915.
Conclusions: Results from this study suggest that using RDV for the treatment of hospitalized patients with COVID-19 is likely to represent a cost-effective use of National Health Service resources at current willingness-to-pay threshold in England and Wales, only if it prevents death. Results needs to be interpreted caution as vaccination was introduced and the SoC and evidence available have also evolved considerably since the analysis is conducted.
Keywords: COVID-19; United Kingdom; coronavirus; cost-effectiveness; economic evaluation; health technology assessment; remdesivir.
. 2022 Feb 20;S1098-3015(22)00044-4.
doi: 10.1016/j.jval.2021.12.015. Online ahead of print.
A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales
Rachid Rafia[SUP] 1 [/SUP], Marrissa Martyn-St James[SUP] 1 [/SUP], Sue Harnan[SUP] 1 [/SUP], Andrew Metry[SUP] 2 [/SUP], Jean Hamilton[SUP] 1 [/SUP], Allan Wailoo[SUP] 1 [/SUP]
Affiliations
- PMID: 35197225
- PMCID: PMC8858417
- DOI: 10.1016/j.jval.2021.12.015
Abstract
Objectives: COVID-19 is associated with significant morbidity and mortality. This study aims to synthesize evidence to assess the cost-effectiveness of remdesivir (RDV) for the treatment of hospitalized patients with COVID-19 in England and Wales.
Methods: A probabilistic cost-effectiveness analysis was conducted informed by 2 large trials and uses a partitioned survival approach to assess short- and long-term clinical consequences and costs associated with COVID-19 in a hypothetical cohort of hospitalized patients requiring supplemental oxygen at the start of treatment. Given that it is uncertain whether RDV reduces death, 2 analyses are presented, assuming RDV either reduces death or does not. Published sources were used for long-term clinical, quality of life, and cost parameters.
Results: Under the assumption that RDV reduces death, the incremental cost-effectiveness ratio for RDV is estimated at £11 881 per quality-adjusted life-year gained compared with standard of care (SoC) (probabilistic incremental cost-effectiveness ratio £12 400). The probability for RDV to be cost-effective is 74% at a willingness-to-pay threshold of £20 000 per quality-adjusted life-year gained. RDV was no longer cost-effective when the hazard ratio for overall survival compared with SoC was >0·915.
Conclusions: Results from this study suggest that using RDV for the treatment of hospitalized patients with COVID-19 is likely to represent a cost-effective use of National Health Service resources at current willingness-to-pay threshold in England and Wales, only if it prevents death. Results needs to be interpreted caution as vaccination was introduced and the SoC and evidence available have also evolved considerably since the analysis is conducted.
Keywords: COVID-19; United Kingdom; coronavirus; cost-effectiveness; economic evaluation; health technology assessment; remdesivir.